University Hospitals Dorset contribute to international Covid-19 therapy evaluation trials 
 

Research teams at University Hospitals Dorset recruited 75 participants for the REGEN-COV arm of the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial, which is the first large enough to determine definitively whether treatment developed by Regeneron reduces mortality in patients hospitalised with severe Covid-19.
 
The trial has demonstrated that the investigational antibody combination reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.  

Dr Martin Schuster Bruce, UHD consultant in critical care and anaesthesia explains:‘We are really excited to hear about the release of the RECOVERY trial data for REGEN-COV, which is an antibody cocktail against COVID -19. The trial showed that in hospitalised patients with severe COVID-19 , who have not mounted a natural antibody response, this cocktail of antibodies saves lives. I am immensely proud of the RECOVERY trial and UHD’s involvement in this world class medical research that has resulted in millions of lives saved’.